Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.
Highlights this week included:
US: Legislation to ban authorized generics during 180-day exclusivity period makes a comeback in Congress (FDA Law Blog)
Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.
General
Experts work on WIPO traditional knowledge draft treaty text (IP Watch)
Australia: Submissions to Senate inquiry on ‘gene patent’ amendments due Friday! (Patentology)
China: Patentability of dosage regime invention in the form of Swiss-type claim under Chinese patent law (jiplp)
US: Legislation to ban authorized generics during 180-day exclusivity period makes a comeback in Congress (FDA Law Blog)
US: Market exclusivity, data exclusivity and S. 3921 (Holman’s Biotech IP Blog)
US: President’s budget proposal increases funding for basic research but seeks to ‘trim’ data exclusivity period and pay-for-delay agreements (Patent Docs)
US: Novozymes’ biofuel enzyme patent survives Danisco invalidity challenge (Patent Docs)
US: Rift between USPTO and DoJ over question of patent-eligibility for isolated genes seems to be continuing: AMP v USPTO (Patent Docs)
Products
Eloxatin (Oxaliplatin) – Sun agrees to briefly stop selling generic Eloxatin (Patent Docs)
Fipronil – US: Valcera files for declaratory judgment of non-infringement and invalidity of patents licensed to Merial based on its planned sale of fipronil-based animal health products (Patent Docs)
Lescol (Fluvastatin) – US: Novartis files patent infringement suit against Mylan following Para IV challenge (Patent Docs)
Losec (Omeprazole) – EU: AstraZeneca v Commission: a reminder – even acting within the law no guarantee that one is safe from allegations of abuse of dominant position (The SPC Blog)
Niaspan (Niacin) – US: Abbott files patent infringement complaint against Sandoz in response to Para IV certification filing (Patent Docs)
Restylane (Hyaluronic acid) – Medicis and Q-Med settle Restylane dispute with Genzyme (Patent Docs)
Seroplex (Escitalopram) – France: Tribunal de Grand: Enantiomer, novelty and inventive step (Kluwer Patent Blog)
Simponi (Golimumab) – US: Bayer appeals claim construction: Bayer v Centocor (PATracer)
Taclones (Betamethasone, Calcipotriene) – US: Leo files patent infringement suit against Perrigo in response to Para IV challenge (Patent Docs)